Key Takeaways
- On July 22, 2026, Lakewood-Amedex Biotherapeutics (LABT) announced resistance data for Nu-3, its antimicrobial candidate approaching Phase 2 trials.
- Serial passage testing demonstrated that Nu-3 does not trigger resistance development in bacteria.
- The antimicrobial works through a physical membrane-disruption approach targeting infected diabetic foot ulcers.
- Testing revealed effectiveness against numerous resistant bacterial strains, including MRSA and VRE.
- Shares of LABT are hovering near their 52-week low at $1.86, with the company carrying a market capitalization of approximately $3.26 million.
On July 22, 2026, Lakewood-Amedex Biotherapeutics (LABT) announced critical resistance testing data for Nu-3, its primary antimicrobial compound. The announcement triggered a dramatic market response, with shares climbing more than 141% during the trading session.
Lakewood-Amedex Biotherapeutics Inc. Common Stock, LABT
The company operates in the clinical development stage with a modest market capitalization of $3.26 million. Prior to today’s rally, shares were changing hands at $1.86, barely above the 52-week low point of $1.66.
Nu-3 belongs to the Bisphosphocin antimicrobial family developed by the company. Its intended application focuses on treating mildly infected diabetic foot ulcers in patients.
The critical discovery: serial passage experiments revealed that Nu-3 does not trigger resistance development in bacteria. This represents a significant achievement for a therapeutic targeting antibiotic-resistant pathogens.
Nu-3 operates differently from conventional antibiotics by physically destroying bacterial cell membranes. This physical mechanism of action creates barriers for bacteria attempting to evolve resistance through traditional pathways.
Laboratory experiments demonstrated Nu-3’s effectiveness against bacteria possessing diverse resistance capabilities. These encompassed modified antibiotic targets, direct antibiotic degradation enzymes, and active efflux transport systems.
Bacterial Strains Under Investigation
Researchers evaluated Nu-3 against 14 distinct bacterial species. The panel included E. coli, S. aureus, P. aeruginosa, K. pneumoniae, and A. baumannii — representing some of the most challenging drug-resistant organisms encountered clinically.
The resistance profile testing encompassed vanA and vanB variants, mecA, rpoB, NDM enzymes, ESBL producers, AmpC, CRE isolates, sul2, and benzalkonium chloride efflux mechanisms. This represents comprehensive coverage of resistance pathways.
Additional testing included PBP2x mutations and metal-tetracycline/H+ antiporter resistance mechanisms. In vitro results showed Nu-3 maintained activity against every tested variant.
Policy Context and Timing
This data release comes after the 27th Public Meeting of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB), which convened on June 16, 2026. The session centered on developing the upcoming five-year National Action Plan addressing antibiotic-resistant bacteria.
The Nu-3 findings support objectives discussed during that policy meeting, which establishes the strategic direction for federal initiatives targeting antimicrobial resistance.
Company insiders control 69.22% of outstanding shares, suggesting significant confidence from management and founding stakeholders.
During the most recent three-month period, no insider transactions involving stock purchases or sales have been recorded.
The company currently produces no revenue and maintains negative operating margins. Its GF Score registers at 8 out of 100, with profitability metrics at 1/10 and financial strength scored at 4/10.
Nu-3 has completed prerequisites for Phase 2 clinical trials targeting mildly infected diabetic foot ulcers. The company has not disclosed a timeline for initiating Phase 2 studies.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
